Loading clinical trials...
Loading clinical trials...
A Multicenter, Double-blind, Randomized, Active-controlled Phase 4 Study to Evaluate the Efficacy and Safety of Tegoprazan in GERD Patients With Nighttime Heartburn
This study aims to compare the nighttime heartburn improvement effect of Tegoprazan 50mg and Esomeprazole 40mg(or 20mg) in patients with GERD.
This is a multi-center, double-blind, randomized, active-controlled phase 4 study. Subjects will be randomly assigned to one of the two treatment groups (tegoprazan 50mg, esomeprazole 40mg or 20mg).
Age
19 - 75 years
Sex
ALL
Healthy Volunteers
No
Severance Hospital
Seoul, South Korea
Start Date
March 24, 2023
Primary Completion Date
December 31, 2024
Completion Date
December 31, 2024
Last Updated
August 3, 2023
338
ESTIMATED participants
Tegoprazan
DRUG
Esomeprazole
DRUG
Lead Sponsor
HK inno.N Corporation
NCT00574327
NCT06585176
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions